MarketWise stock price target raised to $20 from $19 at UBS

Investing.com - UBS raised its price target on MarketWise Inc. (NASDAQ:MKTW) to $20.00 from $19.00 on Thursday, while maintaining a Neutral rating on the stock. According to InvestingPro data, the stock has shown remarkable momentum with a 57.66% return over the past six months, while trading at an attractive P/E ratio of 6.79.

The price target adjustment follows MarketWise’s second-quarter results, which prompted UBS to raise its estimates despite quarterly billings declining sequentially. The company maintains a strong gross profit margin of 86.81% and offers an impressive dividend yield of 8.6%, as revealed by InvestingPro analysis.

UBS noted that the third quarter is starting positively, with July billings exceeding the average monthly billings recorded in the second quarter of 2025.

The financial services firm highlighted that while MarketWise continues to face an uncertain backdrop and declining subscriber numbers, management remains confident in achieving its fiscal year 2025 targets.

UBS specifically pointed to cost management as a positive factor for MarketWise, but indicated it needs "more confidence to move off the sidelines" before changing its Neutral stance on the stock.

In other recent news, MarketWise, Inc. has officially appointed Dr. David "Doc" Eifrig as its permanent Chief Executive Officer. Dr. Eifrig had been serving as the interim CEO since August 2024 and has now been confirmed for the role on a permanent basis. His leadership during the interim period resulted in improved financial performance for the company over the past two quarters. The decision was backed by the company’s Board of Directors, employees, and shareholders, reflecting their confidence in his capabilities. Matthew Turner, Chairman of the MarketWise board, expressed satisfaction with Dr. Eifrig’s appointment, emphasizing the board’s confidence in his leadership. These developments mark a significant step for MarketWise as it continues to focus on its financial research and tools for investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.